Tumor angiogenesis: past, present and the near future
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The concept of treating solid tumors by inhibiting tumor angiogenesis was first articulated almost 30 years ago. For the next 10 years it attracted little scientific interest. This situation changed, relatively slowly, over the succeeding decade with the discovery of the first pro-angiogenic molecules such as basic fibroblast growth factor and vascular endothelial growth factor (VEGF), and the development of methods of successfully growing vascular endothelial cells in culture as well as in vivo assays of angiogenesis. However, the 1990s have witnessed a striking change in both attitude and interest in tumor angiogenesis and anti-angiogenic drug development, to the point where a remarkably diverse group of over 24 such drugs is currently undergoing evaluation in phase I, II or III clinical trials. In this review I will discuss the many reasons for this. These features, together with other recent discoveries have created intense interest in initiating and expanding anti-angiogenic drug discovery programs in both academia and industry, and the testing of such newly developed drugs, either alone, or in various combinations with conventional cytotoxic therapeutics. However, significant problems remain in the clinical application of angiogenesis inhibitors such as the need for surrogate markers to monitor the effects of such drugs when they do not cause tumor regressions, and the design of clinical trials. Also of concern is that the expected need to use anti-angiogenic drugs chronically will lead to delayed toxic side effects in humans, which do not appear in rodents, especially in short-term studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Cited by
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
“These include metabolic stress (for example, low p O 2 , low pH or hypoglycaemia), mechanical stress (for example, pressure generated by proliferating cells), immune/inflammatory response (for example, immune/inflammatory cells that have infiltrated the tissue), and genetic mutations (for example, activation of oncoge…”
BackgroundPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
“The formation of new blood vessels provides a mechanism by which an in situ tumor lesion can circumvent the critical limitations of the oxygen diffusion distance and restrictions on nutrient exchange (Folkman, 1995; Carmeliet, 2000; Carmeliet and Jain, 2000; Kerbel, 2000).”
BackgroundSmall molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
“On the other hand, macrophages have also been found to promote tumor angiogenesis (14) and to secrete a wide range of growth factors which may promote tumor growth (15).”
BackgroundKlement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationCross, M. J., & Claesson-Welsh, L. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01676-x · Cited by 989
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis
Cardone, R. A., Casavola, V., & Reshkin, S. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1713 · Cited by 897
Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma
Hendrix, M. J. C., Seftor, E. A., Hess, A. R., & Seftor, R. E. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1092 · Cited by 824
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
The Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 640
(2003) · PubMed · Cited by 624
Gold Nanoparticles in Cancer Treatment
Sztandera, K., Gorzkiewicz, M., & Klajnert-Maculewicz, B. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00810 · Cited by 607
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Ferrara, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-2 · Cited by 574
Clinical, Cellular, and Molecular Aspects of Cancer Invasion
Mareel, M., & Leroy, A. (2003) · Physiological Reviews · doi:10.1152/physrev.00024.2002 · Cited by 524
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
Rodríguez-Manzaneque, J. C., Lane, T. F., Ortega, M. A., Hynes, R. O., Lawler, J., & Iruela-Arispe, M. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171460498 · Cited by 473
FUKUMURA, D., DUDA, D. G., MUNN, L. L., & JAIN, R. K. (2010) · Microcirculation · doi:10.1111/j.1549-8719.2010.00029.x · Cited by 451
Vascular Growth Factors and Lymphangiogenesis
Jussila, L., & Alitalo, K. (2002) · Physiological Reviews · doi:10.1152/physrev.00005.2002 · Cited by 443
Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice
Pitulescu, M. E., Schmidt, I., Benedito, R., & Adams, R. H. (2010) · Nature Protocols · doi:10.1038/nprot.2010.113 · Cited by 418
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Colavitti, R., Pani, G., Bedogni, B., Anzevino, R., Borrello, S., Waltenberger, J., & Galeotti, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107711200 · Cited by 384
Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Lin, B., Song, X., Yang, D., Bai, D., Yao, Y., & Lu, N. (2018) · Gene · doi:10.1016/j.gene.2018.02.026 · Cited by 384
The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis
Gately, S. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026575610124 · Cited by 359
Molecular basis of angiogenesis and cancer
Tonini, T., Rossi, F., & Claudio, P. P. (2003) · Oncogene · doi:10.1038/sj.onc.1206816 · Cited by 347
Angiogenesis—a new target for future therapy
Pandya, N. M., Dhalla, N. S., & Santani, D. D. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.01.005 · Cited by 345
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
The Pivotal Role of Vascularization in Tissue Engineering
Auger, F. A., Gibot, L., & Lacroix, D. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152428 · Cited by 334
Moser, T. L., Kenan, D. J., Ashley, T. A., Roy, J. A., Goodman, M. D., Misra, U. K., Cheek, D. J., & Pizzo, S. V. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131067798 · Cited by 314
Kubo, H., Cao, R., Bräkenhielm, E., Mäkinen, T., Cao, Y., & Alitalo, K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062040199 · Cited by 305
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
The Macrophage Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression
Lin, E. Y., Gouon-Evans, V., Nguyen, A. V., & Pollard, J. W. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1020399802795 · Cited by 294
Differentiation therapy of human cancer: basic science and clinical applications
Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., & Fisher, P. B. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00132-2 · Cited by 292
Molecular targets for breast cancer therapy and prevention
Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 288
EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer
Shankar, S. (2008) · Frontiers in Bioscience · doi:10.2741/2691 · Cited by 273
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C., Rutka, J. T., & Zadeh, G. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 272
Molecular Determinants of Ovarian Cancer Plasticity
Sood, A. K., Seftor, E. A., Fletcher, M. S., Gardner, L. M. G., Heidger, P. M., Buller, R. E., Seftor, R. E. B., & Hendrix, M. J. C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64079-5 · Cited by 268
Rosen, L. S. (2002) · Cancer Control · doi:10.1177/107327480200902s05 · Cited by 268
Social Support and Physical Health: Models, Mechanisms, and Opportunities
Uchino, B. N., Bowen, K., Kent de Grey, R., Mikel, J., & Fisher, E. B. (2018) · Principles and Concepts of Behavioral Medicine · doi:10.1007/978-0-387-93826-4_12 · Cited by 257
Corbacho, A., Martinez De La Escalera, G., & Clapp, C. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1730219 · Cited by 256
Molecular mechanisms of anti-angiogenic effect of curcumin
Gururaj, A. E., Belakavadi, M., Venkatesh, D. A., Marmé, D., & Salimath, B. P. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02306-9 · Cited by 253
HIF-1: Using Two Hands to Flip the Angiogenic Switch
Semenza, G. L. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026544214667 · Cited by 248
“This process, which is referred to as the angiogenic switch, results from a relative increase in the expression of angiogenic factors and a relative decrease in the expression of anti-angiogenic factors [5,6].”
InfluentialLi, N., Chen, X., Liao, J., Yang, G., Wang, S., Josephson, Y., Han, C., Chen, J., Huang, M.-T., & Yang, C. S. (2002) · Carcinogenesis · doi:10.1093/carcin/23.8.1307 · Cited by 217
Yue, P. Y. K., Mak, N. K., Cheng, Y. K., Leung, K. W., Ng, T. B., Fan, D. T. P., Yeung, H. W., & Wong, R. N. S. (2007) · Chinese Medicine · doi:10.1186/1749-8546-2-6 · Cited by 211
“tumors) could be treated using angiogenic inhibitors to shut down the formation of neovessels [70-72] (Table 2).”
Khanna, C., Prehn, J., Yeung, C., Caylor, J., Tsokos, M., & Helman, L. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1006767007547 · Cited by 207
“The angiogenic switch describes a biological event wherein a tumor cell acquires or turns on the appropriate apparatus for blood vessel formation [34, 36].”
BackgroundMizukami, Y., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., & Chung, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3017 · Cited by 165
“Vascular endothelial growth factor (VEGF) is a key proangiogenic factor, and therapeutic approaches that inhibit VEGF in human malignancies now are in clinical trials (2, 3).”
BackgroundVascular endothelial growth factor and social support in patients with ovarian carcinoma
Lutgendorf, S. K., Johnsen, E. L., Cooper, B., Anderson, B., Sorosky, J. I., Buller, R. E., & Sood, A. K. (2002) · Cancer · doi:10.1002/cncr.10739 · Cited by 160
Stéphanou, A., McDougall, S. R., Anderson, A. R. A., & Chaplain, M. A. J. (2005) · Mathematical and Computer Modelling · doi:10.1016/j.mcm.2005.05.008 · Cited by 160
“Experimentally, alteration of the vasculature is made possible by the use of anti-vascular factors [31-33].”
BackgroundTumor angiogenesis – A potential target in cancer chemoprevention
Bhat, T. A., & Singh, R. P. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.08.032 · Cited by 160
Wang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.09.054 · Cited by 127
Ward, N. L., & Lamanna, J. C. (2004) · Neurological Research · doi:10.1179/016164104x3798 · Cited by 122
Liu, D., Liu, F., Liu, Z., Wang, L., & Zhang, N. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200402e · Cited by 108
Combination of nanotechnology with vascular targeting agents for effective cancer therapy
Jahanban‐Esfahlan, R., Seidi, K., Banimohamad‐Shotorbani, B., Jahanban‐Esfahlan, A., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26051 · Cited by 84
Kurebayashi, J., Otsuki, T., Kurosumi, M., Soga, S., Akinaga, S., & Sonoo, H. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02159.x · Cited by 60
Cappelli, H. C., Kanugula, A. K., Adapala, R. K., Amin, V., Sharma, P., Midha, P., Paruchuri, S., & Thodeti, C. K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.07.042 · Cited by 54
Involvement of RB gene family in tumor angiogenesis
Gabellini, C., Del Bufalo, D., & Zupi, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209631 · Cited by 47
“…between several factors promoting or suppressing angiogenesis and the induction of the so-called ‘angiogenic switch’ is determined by proangiogenic factors overcoming the antiangiogenic ones (Folkman, 1995; Beck and D’Amore, 1997; Ferrara, 2000; Kerbel, 2000; Li et al., 2000, Tonini et al., 2003).”
BackgroundBlood vessels and Parkinsonism
Barcia, C. (2004) · Frontiers in Bioscience · doi:10.2741/1145 · Cited by 41
“For example, hypoxia, hypoglycemia, or inflammation are triggers for an angiogenic response (31, 32, 33, 34).”
Background
Metadata
- Authors
- Kerbel, R. S.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03
- Volume
- 21
- Issue
- 3
- Pages
- 505-515
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2150048971
- Cited by
- 976
- References
- 150
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.